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PreviewsAnother important finding that might
be critical to understanding the mecha-
nism of NPC1-mediated cholesterol
efflux is that NPC1 contains a second
sterol-binding site. The authors predicted
that NPC1 might have more than one
sterol-binding site because of inconsis-
tencies between the structure-activity
studies of the oxysterol derivatives and
the crystal structure of the N-terminal
cholesterol-binding site (head piece)
(Kwon et al., 2009). To test their hypoth-
esis, they constructed an I1061T trunca-
tion mutant lacking the head piece (i.e.,
a ‘‘headless’’ NPC1 protein with amino
acids 25–248 deleted). The oxysterol
derivatives still rescued the ‘‘headless’’
NPC1-I1061T construct, and photo-
affinity labeling studies showed that the
‘‘headless’’ NPC1 contains an additional
sterol-binding site. This finding is signifi-
cant, because it suggests that the 13
TM segments may form a pore that
contains a sterol-binding site(s) or the
translocation pathway for sterol efflux.
The second sterol-binding site may also
be important for transferring cholesterol
molecules from NPC1 to an unknown298 Chemistry & Biology 20, March 21, 2013cytosolic cholesterol carrier (Figure 1,
step e).
The present study provides an impor-
tant starting point toward understanding
the mechanism of cholesterol efflux from
endo-lysosomes. It also provides evi-
dence that it might be worthwhile to
screen chemical libraries for small mole-
cules that might be better pharmacolog-
ical chaperones that may or may not
bind to a site that is different than the
second sterol-binding site. The oxysterol
derivates in this study or compounds
identified through future high throughput
screening of chemical libraries could
then be used to study the biochemistry
of NPC1 and, more importantly, could
be tested for toxicity and efficacy in clin-
ical trials. Future studies on NPC1 and
the rescue of NPC1 mutants will be very
exciting. Stay tuned.ACKNOWLEDGMENTS
This work was supported by grants from the Cana-
dian Institutes of Health Research and Cystic
Fibrosis Canada. D.M.C. holds the Canada
Research Chair in Membrane Biology.ª2013 Elsevier Ltd All rights reservedREFERENCES
Carstea, E.D., Morris, J.A., Coleman, K.G., Loftus,
S.K., Zhang, D., Cummings, C., Gu, J., Rosenfeld,
M.A., Pavan, W.J., Krizman, D.B., et al. (1997).
Science 277, 228–231.
Chen, E.Y., Bartlett, M.C., Loo, T.W., and Clarke,
D.M. (2004). J. Biol. Chem. 279, 39620–39627.
Gelsthorpe, M.E., Baumann, N., Millard, E., Gale,
S.E., Langmade, S.J., Schaffer, J.E., and Ory,
D.S. (2008). J. Biol. Chem. 283, 8229–8236.
Karten, B., Peake, K.B., and Vance, J.E. (2009).
Biochim. Biophys. Acta 1791, 659–670.
Kwon, H.J., Abi-Mosleh, L., Wang, M.L., Dei-
senhofer, J., Goldstein, J.L., Brown, M.S., and
Infante, R.E. (2009). Cell 137, 1213–1224.
Loo, T.W., and Clarke, D.M. (1997). J. Biol. Chem.
272, 709–712.
Loo, T.W., and Clarke, D.M. (1998). J. Biol. Chem.
273, 14671–14674.
Loo, T.W., Bartlett, M.C., and Clarke, D.M. (2002).
J. Biol. Chem. 277, 27585–27588.
Ohgane, K., Karaki, F., Dodo, K., and Hashimoto,
Y. (2013). Chem. Biol. 20, this issue, 391–402.
Park, W.D., O’Brien, J.F., Lundquist, P.A., Kraft,
D.L., Vockley, C.W., Karnes, P.S., Patterson,
M.C., and Snow, K. (2003). Hum. Mutat. 22,
313–325.Resurrecting the Protein Fold
for Disease InterventionRichard N. Sifers1,*
1Department of Pathology and Immunology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
*Correspondence: rsifers@bcm.edu
http://dx.doi.org/10.1016/j.chembiol.2013.03.002
Because proteostasis networks manage the cellular proteome, their pharmacological manipulation might
correct pathologies associated with numerous protein misfolding diseases. In this issue of Chemistry &
Biology, Tong Ong and colleagues identify a novel biosynthetic juncture for glucocerebrosidase as a site
for therapeutic intervention in Gaucher’s disease.Pathologies associated with numerous
genetically-inherited conformational dis-
orders are directly manifested at the level
of the encoded protein (Kopito and Ron,
2000). The commonality among this
diverse set of disorders is the failure of
a mutant polypeptide to attain native
structure following biosynthesis, which is
often accompanied by selective pro-teolytic elimination. Intervention at this
posttranslational juncture, rather than
the alteration of an aberrant nucleotide
sequence, may provide therapeutic strat-
egies capable of correcting numerous
inherited loss-of-function disorders.
Pursuit of this novel therapeutic
endeavor was initially hindered by the
false assumption that an aberrant aminoacid sequence is solely responsible for
impairing protein conformational matura-
tion. In reality, protein folding is also in-
fluenced by the environment into which
the polypeptide is translated (Anfinsen,
1973). In support of this notion, living cells
are able to regulate numerous compart-
ment-specific stress response pathways
(Christianson et al., 2011) as a means
Figure 1. Differential Fates for Newly Synthesized Mutant GC
The biosynthetic maturation (green) and degradation (red) itineraries for the
newly synthesized GC polypeptide are depicted. Relevant PN components
that contribute to each step accompany the arrows. The key finding is that
the concentration of FKBP10 represents a set point (triangle) that can appar-
ently balance the entrance of the GC polypeptide into either route. The deple-
tion of FKBP10 is sufficient to promote a fraction of mutant GC polypeptides to
successfully complete the biosynthetic route.
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folding itineraries. Recent
success in exploiting the
cellular proteostasis network
(PN) (Balch et al., 2008), at
least at the cellular level
(Tong Ong et al., 2010),
supports further exploration
of this novel therapeutic
juncture.
Although many conforma-
tional disorders may eventu-
ally be amenable to some
form of pharmacological
intervention, the correction
of lysosomal storage dis-
eases represents a preferred
therapeutic target for two
central reasons. First, the
newly synthesized acid
hydrolases are initially trans-
located into the endoplasmic
reticulum (ER) lumen during
biosynthesis, where a com-
partment-specific PN (Balch
et al., 2008) dictates their
deployment to lysosomes,where they become active. Several
mutant variants, however, fail to attain
native structure and are targeted for
proteasomal degradation, rather than
deployment, making them an attractive
model for therapeutic intervention.
Second, the overall therapeutic goal is
quite modest, considering that, in most
cases, a 10% increase in the lysosomal
enzyme concentration is considered suffi-
cient to correct the corresponding physio-
logical abnormality (Sawkar et al., 2006).
An initial challenge for Tong Ong et al.
(2013; in this issue ofChemistry & Biology)
was to advance their current under-
standing of how the ER-specific PN oper-
ates for a specific mutant acid hydrolase.
The immediate objective was to identify
key PN components that could alter the
fate of newly synthesized glucocerebrosi-
dase (GC), the deficiency of which is
responsible for Gaucher’s disease (Saw-
kar et al., 2006). In addition to its role in
disease pathogenesis, mutant GC was
chosen because of its well characterized
biosynthetic and trafficking itineraries
(Reczek et al., 2007). Previous studies
have demonstrated that productive fold-
ing of the newly synthesized polypep-
tide involves physical interaction with
calnexin, an ER chaperone for N-linked
glycoproteins (Cabral et al., 2001). Subse-quent binding to LIMP-2 delivers the
correctly folded molecule to lysosomes
(Reczek et al., 2007), independent of
the classical mannose-6-phosphate traf-
ficking pathway used by many other acid
hydrolases. Finally, proteasomal degra-
dation is the fate for GC mutants unable
to undergo successful conformational
maturation following biosynthesis.
The utilization of comparative proteo-
mics provided a method to identify novel
PN components whose concentrations
were anticipated to change in response
to treating fibroblasts from specific
Gaucher’s patients with established pro-
teostasis regulators (Tong Ong et al.,
2010). A combination of diverse method-
ologies identified LIMP-2 and FKBP10
as PN components responsible for
managing the fate of mutant GC. Because
the role of LIMP-2 was already known,
additional investigations focused on the
unexpected contribution of FKBP10.
which is a prolyl cis-trans isomerase that
contributes to the structural maturation
of collagen chains (Barnes et al., 2012).
Briefly, the consequences ofmanipulating
the intracellular concentration of FKBP10
led to the identification of a novel early
juncture in the biosynthetic maturation of
mutant GC. The quantitative trait was
shown to coordinate a previously un-Chemistry & Biology 20, March 21, 2013 ª2013 Elseappreciated early discrimina-
tory step capable of pro-
moting the entrance of
mutant GC into a calnexin-
mediated folding pathway
in response to lowering
FKBP10 concentrations. In
contrast, elevated concentra-
tions promoted entrance into
the proteasomal degrada-
tion pathway (Figure 1). For
the purposes of therapeutic
intervention, experimental
depletion of FKBP10 was
performed. The manipulation
prevented mutant GC degra-
dation in a manner that
allowed a fraction of the
molecules to interact with
calnexin and undergo LIMP-
2-mediated delivery to lyso-
somes with a concomitant
gain of GC enzymatic activity.
The approach taken by
Tong Ong et al. (2013) has
identified a previously unap-
preciated role for FKBP10. Inaddition to functioning as a prolyl cis-
trans isomerase, it can apparently help
balance the fate of newly synthesized
GC. Additional studies are needed to
define the exact mechanism through
which its concentration regulates this
early decision-making process. It is
important to note that their observation
establishes the notion that the PN does
not function to merely promote and eval-
uate protein structural quality as once
believed (Cabral et al., 2001). Rather, it is
apparently capable of balancing protein
fate. Whether this capacity includes
a decision-making function capable of
eliminating wild-type protein folding inter-
mediates that are not needed, awaits
additional investigation.
Considering that protein fates are
not necessarily predetermined and are
actually a continuum of outcomes that
depend, at least to some extent, on the
existence of a flexible PN, the eventual
pharmaceutical management of the
system could lead to the discovery of
multiple therapeutic strategies capable
of correcting pathologies associated
with numerous conformational diseases.
With regard to the concern that the
proposed intervention strategy might
actually disrupt the global folding environ-
ment, numerous folding itineraries arevier Ltd All rights reserved 299
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Previewsknown to simultaneously operate in the
ER, so the transient disruption of a single
PN component will not necessarily disturb
the function of others. Additionally,
because the inheritance of inactive
FKBP10 is responsible for a form of osto-
genesis imperfecta (Barnes et al., 2012),
one might ask if the treatment strategy
could possibly avoid the development of
an additional disorder. Conceivably, opti-
mization of a dosing regime for some-
thing like an RNAi-mediated knockdown
strategy in a preclinical model, for ex-
ample, could possibly maintain the
FKBP10 concentration at a therapeutic
level. Despite the future efforts that may
unfold, at least for now, the findings of
Tong Ong et al. (2013) attest to the possi-
bility that pharmaceutical management
of a flexible PN may someday serve as300 Chemistry & Biology 20, March 21, 2013a therapeutic option to correct the pathol-
ogies associated with numerous confor-
mational diseases.ACKNOWLEDGMENTS
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